Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab...
4 KB (301 words) - 20:47, 1 December 2023
Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab...
38 KB (4,316 words) - 10:24, 26 August 2024
development targeting PD-1 receptors (checkpoint inhibitors) include pidilizumab (CT-011, Cure Tech) and BMS-936559 (Bristol Myers Squibb). Both atezolizumab...
39 KB (5,010 words) - 05:27, 17 August 2024
toll-like receptor (TLR) agonists, CD40 agonists, anti-PD-1 (pembrolizumab, pidilizumab, and nivolumab) and PD-L1 antibodies. Evidence suggests that anti-PD-1...
154 KB (16,086 words) - 21:51, 24 October 2024
Pexelizumab scFv humanized C5 reduction of side effects of cardiac surgery Pidilizumab mab humanized PD-1 cancer and infectious diseases Pinatuzumab vedotin...
137 KB (4,083 words) - 21:25, 19 October 2024
Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab...
2 KB (87 words) - 01:28, 30 May 2023
expression of various genes; and 6) Checkpoint inhibitors nivolumab, pidilizumab, and pembrolizumab to promote the immune system's ability to suppress...
67 KB (7,967 words) - 13:33, 14 October 2024